Post-marketing safety concern of PI3K inhibitors in the cancer therapies: an 8-year disproportionality analysis from the FDA adverse event reporting system-Reference-Cited by-同舟云学术

Post-marketing safety concern of PI3K inhibitors in the cancer therapies: an 8-year disproportionality analysis from the FDA adverse event reporting system

Published:2024-07-31 Issue: Volume: Page:
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Wu Lisha¹²,Huang Hongyan³,Zhang Yimin⁴,Zhuang Wei⁵^ORCID,Lin Xiaorong⁴⁶^ORCID

Affiliation:

1. Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

2. Department of Oncology, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Shanwei, Guangdong, China

3. Department of Breast Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China

4. Clinical Research Center, Shantou Central Hospital, Shantou, Guangdong, China

5. Department of Pharmacy, Women and Children’s Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China

6. Diagnosis and Treatment Center of Breast Diseases, Shantou Central Hospital, Shantou, Guangdong, China

Funder

National Natural Science Foundation of China

Basic Research and Application of Guangzhou Science and Technology Planning Project

Beijing Xisike Clinical Oncology Research Foundation

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2024.2387317

Reference46 articles.

1. Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition;Maheshwari S;Journal of Biological Chemistry,2017

2. High Frequency of Mutations of the PIK3CA Gene in Human Cancers

3. Genetic and functional analysis of the PIK3CA oncogene in human cancers;Samuels Y;Cancer Res,2006

4. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

5. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma;Lampson BL;Expert Opinion on Investigational Drugs,2017